A Comparative Study of Oral Cyclosporine and Betamethasone Minipulse Therapy in the Treatment of Alopecia Areata
Annals of Dermatology
;
: 569-574, 2016.
Article
in English
| WPRIM
| ID: wpr-59033
ABSTRACT
BACKGROUND:
Various systemic agents have been assessed for the treatment of alopecia areata (AA); however, there is a paucity of comparative studies.OBJECTIVE:
To assess and compare cyclosporine and betamethasone minipulse therapy as treatments for AA with regard to effectiveness and safety.METHODS:
Data were collected from 88 patients who received at least 3 months of oral cyclosporine (n=51) or betamethasone minipulse therapy (n=37) for AA. Patients with ≥50% of terminal hair regrowth in the alopecic area were considered responders.RESULTS:
The responder of the cyclosporine group was 54.9% and that of the betamethasone minipulse group was 37.8%. In the cyclosporine group, patients with mild AA were found to respond better to the treatment. Based on the patient self-assessments, 70.6% of patients in the cyclosporine group and 43.2% of patients in the betamethasone minipulse group rated their hair regrowth as excellent or good. Side effects were less frequent in the cyclosporine group.CONCLUSION:
Oral cyclosporine appeared to be superior to betamethasone minipulse therapy in terms of treatment effectiveness and safety.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Self-Assessment
/
Betamethasone
/
Treatment Outcome
/
Cyclosporine
/
Pulse Therapy, Drug
/
Alopecia
/
Alopecia Areata
/
Hair
Limits:
Humans
Language:
English
Journal:
Annals of Dermatology
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS